| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| Down regulation of cell surface ErbB 1 or ErbB 2 by intracellular expression of specific antibodies has allowed us to delineate the role of these receptors during signaling elicited by : EGF and heparin binding EGF ( HB EGF ) , ligands of ErbB 1 ; betacellulin ( BTC ) , a ligand of ErbB 1 and ErbB 4 ; and neu differentiation factor ( NDF ) , a ligand of ErbB 3 and ErbB 4 . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| Epidermal growth factor and betacellulin mediate signal transduction through co expressed ErbB 2 and ErbB 3 receptors . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| The oncogenic ErbB 2 / ErbB 3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin . ^^^ In addition , when co expressed , blocking either receptor by using site specific antibodies inhibited EGF and betacellulin activities , indicating strict cooperativity between ErbB 3 and ErbB 2 . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| Betacellulin induced the tyrosine phosphorylation of ErbB 1 , ErbB 2 and ErbB 4 . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| Betacellulin , a ligand for EGFR , ErbB 3 , and ErbB 4 , induced DNA synthesis of HASM cells and stimulated signaling through the activation of EGFR and ErbB 2 but not of ErbB 3 and ErbB 4 . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| The erbB 4 gene encodes a detected receptor protein that possesses intrinsic tyrosine kinase activity and belongs to the family of the epidermal growth factor receptor ( EGFR ) ; erbB 4 is stimulated by the heregulins and betacellulin , which enables this receptor to form heterodimers with erbB 2 , a prerequisite for erbB 2 activation . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| Expression of mRNA for the ligands EGF and betacellulin and of the receptors HER 1 and HER 2 were similar in all lines investigated , except LNCaP cells which exhibit low expression of HER 1 . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| The developed method has enabled us to demonstrate that prostate stromal cells in primary culture express EGF , heparin binding EGF ( HB EGF ) , amphiregulin , betacellulin , and epiregulin as well as the HER 1 and HER 2 receptors , whereas no transforming growth factor alpha mRNA is found . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| The mRNA content for six ligands [ EGF , transforming growth factor alpha ( TGF alpha ) , amphiregulin ( AR ) , betacellulin ( betaCL ) , heparin binding EGF like growth factor ( HB EGF ) , epiregulin ( EPI ) ] and two receptors [ EGF receptor 1 Human EGF Receptor ( HER 1 ) and 2 ( HER 2 ) ] was examined by a newly developed quantitative reverse transcription PCR method . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| RESULTS : Prostate tissue expressed the EGF receptor ( HER 1 ) and HER 2 , and the ligands EGF , transforming growth factor alpha ( TGFalpha ) , heparin binding ( HB ) EGF , betacellulin and amphiregulin . ^^^ Treatment with finasteride produced greater concentrations of amphiregulin ( P < 0 . 05 ) than did placebo , did not change the level of TGFalpha , HER 1 and HER 2 , and tended to decrease the concentration of EGF , betacellulin and HB EGF in prostate tissue . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| Stimulation of the duct cells with epidermal growth factor ( EGF ) and betacellulin results in Tyr phosphorylation of ErbB 1 and ErbB 2 , followed by activation of Shc , MEK1 / 2 and ERK1 / 2 . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| We studied epithelial expression of EGF , transforming growth factor a , amphiregulin , heregulin ( HRG ) , betacellulin ( BTC ) , and their receptors , EGFR , HER 2 , and HER 3 , by immunohistochemical analysis in resected bronchial tissue from 20 subjects with ( forced expiratory volume in 1 second [ FEV ( 1 ) ] < 75 % of predicted value ) and 18 without ( FEV ( 1 ) > 85 % predicted value ) COPD . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| BTC induced phosphorylation of all three EGF receptors present on HUVECs : ErbB 2 , ErbB 3 , and ErbB 4 . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| BTC induced phosphorylation of all four EGF receptors present on HTASMCs : ErbB 1 , ErbB 2 , ErbB 3 , and ErbB 4 . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| BTC also phosphorylated ErbB 2 at Tyr 877 , Tyr 1112 , and Tyr 1248 and induced association of ErbB 2 with EGFR , suggesting their heterodimerization in VSMCs . ^^^ In summary , BTC promotes growth and migration of VSMCs through activation of EGFR , ErbB 2 , and downstream serine / threonine kinases . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| The results also suggest that activation of the EGFR plays an important role in development of BTC in this model and that targeting both the EGFR and erbB 2 may be an effective strategy for treatment of this disease . . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| Six genes were over expressed ( ERBB 2 , TGFA , HB EGF , AREG , EREG and EPGN ) , 3 were under expressed ( ERBB 1 , ERBB 4 and NRG 4 ) and 2 were over or under expressed ( ERBB 3 and BTC ) . ^^^ |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P35070 and P04626 |
Pubmed |
SVM Score :0.0 |
| NA |
|